(Q33900921)

29 July 2017

1 reference

title

A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care (English)

1 reference

29 July 2017

1 reference

1 reference

Lyman GH

1

1 reference

29 July 2017

publication date

1 April 2000

1 reference

European Journal of Cancer

29 July 2017

published in

1 reference

29 July 2017

volume

36 Suppl 1

1 reference

29 July 2017

page(s)

S15-21

1 reference

Hematopoietic growth factors. Biology and clinical applications

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

Consensus on the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: an international viewpoint

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

The economics of febrile neutropenia: implications for the use of colony-stimulating factors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900257-9

7 January 2021

10.1016/S0959-8049(99)00257-9

Identifiers

DOI

1 reference

29 July 2017

1 reference